WebShares of the clinical-stage biopharmaceutical company, Oncternal Therapeutics, ( NASDAQ: ONCT) cratered in morning trading on Tuesday after the company announced a “strategic reprioritization” and halted two cancer studies. This included the Phase 3 study and the Phase 1 study of zilovertamab in combination with ibrutinib. The company also ... WebInsider Purchases - Short Term Profit Analysis. In this section, we analyze the profitability of every unplanned, open-market insider purchase made by Marc Steven Hanover in ONCT / Oncternal Therapeutics Inc. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following.
ONCT Stock Data and Insider Activity - quiverquant.com
Web04. apr 2024. · How much insider selling is happening at Oncternal Therapeutics? Insiders have sold a total of 3,669 Oncternal Therapeutics shares in the last 24 months for a total … Web04. apr 2024. · ONCT market cap is currently $46.39M and has a P/E ratio of -0.94. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their ... prolific sim card reader software
ONCT Stock Data and Insider Activity - quiverquant.com
Web23. feb 2024. · Overview of insider trading in Oncternal Therapeutics, Inc.. Insider overview, share value development, latest insider transactions and email notifications … WebOncternal Therapeutics Inc (NASDAQ:ONCT) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds (or held ... WebFind out the latest and most up-to-date insider trades for Oncternal Therapeutics Inc (ONCT) at GuruFocus.com. 🚀 Enjoy a 7-Day Free Trial Thru Apr 02, 2024! Sign Up label printers compatible with stamps.com